Home › Free Stock Grades › GRAL
GRAIL Inc. (GRAL) Stock Grade
GRAL · Healthcare
A+
Market Cap
$3.1B
P/E Ratio
—
Revenue Growth (YoY)
+17.2%
Net Margin
-277.5%
Return on Equity
—
Dividend Yield
None
About GRAIL Inc.'s fundamentals
GRAIL Inc. is a biotechnology company with a market capitalization of $3.1 billion that is growing revenues at a strong pace of 17.2% year-over-year. However, the company is currently unprofitable, reporting a net margin of -277.5% and a net loss in its latest annual statement, indicating it is spending substantially more than it generates in revenue. The company does not pay a dividend, which is typical for early-stage biotech firms prioritizing research and development investments. Profitability metrics like P/E ratio and return on equity are not meaningful given the company's current loss-making status.